Verastem Stock Price, News & Analysis

Verastem Oncology (VSTM), a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 4, 2025, at 4:20 pm ET in New York. Investors and interested parties can access a live webcast of the presentation through the "Events & Presentations" section of Verastem's website, with a replay available for approximately 90 days afterward.

Verastem Oncology (VSTM), a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, has announced its management team's participation in three upcoming investor conferences in May 2025:

• H.C. Wainwright BioConnect Conference: Fireside chat on May 20 at 12:00 PM ET
• RBC Capital Markets Healthcare Conference: Fireside chat on May 20 at 3:35 PM ET
• A.G.P. Healthcare Company Showcase: Virtual fireside chat on May 21 at 10:20 AM ET

Live webcasts will be available on Verastem's website with replays archived for approximately 90 days.

Verastem Oncology (VSTM) has secured a $75 million private placement through a combination of common stock and pre-funded warrants. The company is offering shares at $7.00 per share for approximately $24 million, and $51 million in pre-funded warrants at $6.9999 per warrant with a $0.0001 exercise price.

The placement was led by RTW Investments, with participation from BVF Partners, Nantahala Capital, Octagon Capital, OrbiMed, and Stonepine Capital Management. The closing is expected around April 28, 2025.

The proceeds will fund:

• Potential launch of avutometinib and defactinib in recurrent low-grade serous ovarian cancer
• Continued clinical development of products including VS-7375
• Working capital and general corporate purposes

Verastem Oncology (VSTM) has received FDA clearance for its Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D inhibitor. The company plans to initiate a Phase 1/2a trial in mid-2025 for advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers.

Initial data from partner GenFleet Therapeutics' Phase 1/2 study showed promising results with oral bioavailability and no dose-limiting toxicities across six dose levels, achieving partial responses in pancreatic and advanced lung cancer patients. The upcoming trial's starting dose will be based on GenFleet's efficacy findings to accelerate progress.

GenFleet will present preliminary dose escalation results at the 2025 ASCO Annual Meeting in Chicago (May 30-June 3). The abstract (#3013) is embargoed until May 22, 2025.

Verastem Oncology (VSTM) has announced new equity compensation grants to fifteen employees. The company granted stock options to purchase 164,500 shares of common stock to fourteen new employees at an exercise price of $5.82 per share, matching the closing price on April 1, 2025. Additionally, one new employee received 83,333 restricted stock units.

The grants were made under Nasdaq's inducement grant exception (Rule 5635(c)(4)). The stock options and 50,000 RSUs will vest 25% after one year, with remaining shares vesting quarterly over three years. The additional 33,333 RSUs will vest based on sales milestone achievements. All vestings are contingent on continued employment with Verastem Oncology.